HRP20220639T1 - Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe - Google Patents
Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20220639T1 HRP20220639T1 HRP20220639TT HRP20220639T HRP20220639T1 HR P20220639 T1 HRP20220639 T1 HR P20220639T1 HR P20220639T T HRP20220639T T HR P20220639TT HR P20220639 T HRP20220639 T HR P20220639T HR P20220639 T1 HRP20220639 T1 HR P20220639T1
- Authority
- HR
- Croatia
- Prior art keywords
- fviii
- pharmaceutical preparation
- bleeding
- chimeric polypeptide
- preparation according
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title claims 48
- 229920001184 polypeptide Polymers 0.000 title claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 21
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 21
- 108010054218 Factor VIII Proteins 0.000 claims 47
- 102000001690 Factor VIII Human genes 0.000 claims 47
- 239000000825 pharmaceutical preparation Substances 0.000 claims 18
- 208000032843 Hemorrhage Diseases 0.000 claims 13
- 208000034158 bleeding Diseases 0.000 claims 13
- 230000000740 bleeding effect Effects 0.000 claims 13
- 238000001356 surgical procedure Methods 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 3
- 238000007917 intracranial administration Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010028309 Muscle haemorrhage Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 206010061249 Intra-abdominal haemorrhage Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 238000007428 craniotomy Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002297 emergency surgery Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims 1
- 208000002085 hemarthrosis Diseases 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000013150 knee replacement Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000000574 retroperitoneal space Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000007483 tonsillectomy Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
Claims (19)
1. Farmaceutski pripravak, koji sadrži
(i) kimerni polipeptid, koji sadrži dio Faktora VIII (FVIII) i drugi dio, te
(ii) najmanje jednu farmaceutski prihvatljivu pomoćnu tvar,
naznačen time što je
(1) 25% do 40% FVIII dijela kimernog polipeptida jednolančani FVIII i
(2) 60% do 75% FVIII dijela kimernog polipeptida je obrađeni FVIII, pri čemu jednolančani FVIII sadrži FVIII teškog lanca i FVIII lakog lanca na jednom polipeptidnom lancu i obrađeni FVIII sadrži FVIII teškog lanca i FVIII lakog lanca na dva polipeptidna lanca.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time što
(a) 25% do 35% FVIII dijela kimernog polipeptida je jednolančani FVIII, ili
(b) 30% do 40% FVIII dijela kimernog polipeptida je jednolančani FVIII.
3. Farmaceutski pripravak prema zahtjevu 1, naznačen time što
(a) oko 25% FVIII dijela kimernog polipeptida je jednolančani FVIII i oko 75% FVIII dijela kimernog polipeptida je obrađeni FVIII,
(b) oko 30% FVIII dijela kimernog polipeptida je jednolančani FVIII i oko 70% FVIII dijela kimernog polipeptida je obrađeni FVIII, ili
(c) oko 35% FVIII dijela kimernog polipeptida je jednolančani FVIII i oko 65% FVIII dijela kimernog polipeptida je obrađeni FVIII, ili
(d) 40% FVIII dijela kimernog polipeptida je jednolančani FVIII i 60% FVIII dijela kimernog polipeptida je obrađeni FVIII.
4. Farmaceutski pripravak prema bilo kojem od zahtjeva 1-3, naznačen time što kimerni polipeptid koji sadrži jednolančani FVIII ima aktivnost FVIII usporedivu s kimernim polipeptidom koji sadrži obrađeni FVIII.
5. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 4, naznačen time što kimerni polipeptid je dugo djelujući FVIII polipeptid.
6. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time što drugi dio obuhvaća Fc regiju.
7. Farmaceutski pripravak prema zahtjevu 6, naznačen time što kimerni polipeptid je FVIIIFc monomerni dimer hibrid.
8. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 7, naznačen time što FVIII dio sadrži FVIII izbrisan iz B-domene ili pune duljine, zreli FVIII, ili pri čemu ostatak 1645 odgovara punoj dužini, zreli FVIII, ostatak 1648 koji odgovara punoj dužini, mature FVIII, ili oba ostatka u jednom lancu FVIII je supstituiran ili mutiran u usporedbi s divljim tipom FVIII.
9. Farmaceutski pripravak prema zahtjevu 8, naznačen time što FVIII dio sadrži FVIII koji je izbrisan iz B-domene.
10. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9, naznačen time što dio FVIII sadrži aminokiselinsku sekvencu koja je najmanje 95% identična aminokiselinama 20 do 1457 iz SEQ ID NO: 2.
11. Farmaceutski pripravak prema zahtjevu 10, naznačen time što dio FVIII sadrži aminokiselinsku sekvencu identičnu aminokiselinama 20 do 1457 iz SEQ ID NO: 2.
12. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 11, naznačen time što drugi dio sadrži aminokiselinsku sekvencu koja je najmanje 95% identična aminokiselinama 21 do 247 iz SEQ ID NO: 4.
13. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 12, naznačen time što drugi dio sadrži aminokiselinsku sekvencu identičnu aminokiselinama 21 do 247 iz SEQ ID NO: 4.
14. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 13 naznačen time što je prikladan za potkožno, intradermalno, intravaskularno, intravenozno, intramuskularno, spinalno, intrakranijalno, intratekalno, intraokularno, periokularno, intraorbitalno, intrasinovijalno ili intraperitonealno davanje putem injekcije ljudima.
15. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 14, naznačen time što je za uporabu za prevenciju, smanjenje ili liječenje epizode krvarenja kod subjekta, profilaktičko liječenje epizode krvarenja kod subjekta, o liječenje epizode krvarenja na zahtjev kod subjekta, ili za održavanje homeostaze kod subjekta kojem je potreban operativni zahvat.
16. Farmaceutski pripravak za uporabu prema zahtjevu 15, naznačen time što je epizoda krvarenja povezana s bolešću ili stanjem koje se sastoji od hemartroze, krvarenja mišića, oralnog krvarenja, krvarenja, krvarenja u mišiće, oralnog krvarenja, trauma, trauma capitis (ozljede glave), gastrointestinalnog krvarenja, intrakranijalnog krvarenja, intraabdominalnog krvarenja, intratorakalnog krvarenja, prijeloma kostiju, krvarenja u središnjem živčanom sustavu, krvarenja u retrofaringealnom prostoru, krvarenja u retroperitonealnom prostoru, ili krvarenja u iliopsoas ovojnici.
17. Farmaceutski pripravak za uporabu prema zahtjevu 16, naznačen time što je bolest ili stanje hemofilija A.
18. Farmaceutski pripravak za uporabu prema zahtjevu 16, naznačen time što je operacija mala operacija, velika operacija, vađenje zuba, tonzilektomija, ingvinalna herniotomija, sinovektomija, cjelokupna zamjena koljena, kraniotomija, osteosinteza, operacija ozljede, intrakranijalna operacija, intraabdominalna operacija, intratorakalna operacija, hitna operacija, ili operacija zamjene zglobova.
19. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 14, ili farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 15-18, naznačen time što je liofiliziran.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161506015P | 2011-07-08 | 2011-07-08 | |
| US201161522647P | 2011-08-11 | 2011-08-11 | |
| US201161541561P | 2011-09-30 | 2011-09-30 | |
| US201161569158P | 2011-12-09 | 2011-12-09 | |
| US201261586443P | 2012-01-13 | 2012-01-13 | |
| US201261622789P | 2012-04-11 | 2012-04-11 | |
| US201261657641P | 2012-06-08 | 2012-06-08 | |
| EP18211156.7A EP3513804B1 (en) | 2011-07-08 | 2012-07-06 | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220639T1 true HRP20220639T1 (hr) | 2022-07-08 |
Family
ID=47506823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220639TT HRP20220639T1 (hr) | 2011-07-08 | 2012-07-06 | Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe |
| HRP20190535TT HRP20190535T1 (hr) | 2011-07-08 | 2019-03-19 | Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190535TT HRP20190535T1 (hr) | 2011-07-08 | 2019-03-19 | Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10010622B2 (hr) |
| EP (3) | EP4169525A1 (hr) |
| JP (5) | JP2014522838A (hr) |
| KR (2) | KR101829603B1 (hr) |
| CN (2) | CN103796670A (hr) |
| AR (1) | AR087091A1 (hr) |
| AU (3) | AU2012282875B2 (hr) |
| BR (1) | BR112014000466A2 (hr) |
| CA (1) | CA2841066C (hr) |
| CL (1) | CL2014000024A1 (hr) |
| CO (1) | CO6940381A2 (hr) |
| CY (1) | CY1122900T1 (hr) |
| DK (2) | DK3513804T3 (hr) |
| EA (1) | EA029045B1 (hr) |
| ES (2) | ES2722209T3 (hr) |
| HR (2) | HRP20220639T1 (hr) |
| HU (1) | HUE043763T2 (hr) |
| IL (2) | IL230333B (hr) |
| LT (2) | LT3513804T (hr) |
| MX (1) | MX350581B (hr) |
| MY (1) | MY180714A (hr) |
| PL (2) | PL3513804T3 (hr) |
| PT (2) | PT3513804T (hr) |
| RS (2) | RS58578B1 (hr) |
| SI (2) | SI2729161T1 (hr) |
| TW (3) | TWI764092B (hr) |
| WO (1) | WO2013009627A2 (hr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2077121T3 (pl) * | 2003-05-06 | 2011-07-29 | Syntonix Pharmaceuticals Inc | Białka chimeryczne o strukturze czynnik krzepliwości krwi VII-FC do leczenia zaburzenia hemostatycznego |
| CN103804489A (zh) | 2006-12-15 | 2014-05-21 | 巴克斯特国际公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| HUE028056T2 (en) | 2009-07-27 | 2016-11-28 | Baxalta GmbH | Blood coagulation protein conjugates |
| DK2459224T3 (en) | 2009-07-27 | 2016-07-25 | Baxalta GmbH | Blodstørkningsproteinkonjugater |
| CN102573920B (zh) | 2009-07-27 | 2015-01-14 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
| SG181130A1 (en) | 2009-12-06 | 2012-07-30 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| CA2822591C (en) | 2010-12-22 | 2020-12-29 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
| DK3513804T3 (da) * | 2011-07-08 | 2022-06-20 | Bioverativ Therapeutics Inc | Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf |
| US10317376B2 (en) | 2012-04-11 | 2019-06-11 | Bioverativ Therapeutics Inc. | Methods of detecting glycosaminoglycans |
| EP2858659B1 (en) | 2012-06-08 | 2019-12-25 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
| EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | CHIMERIC COAGULATION FACTORS |
| US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
| US20150266944A1 (en) * | 2012-10-30 | 2015-09-24 | Biogen Idec Ma Inc. | Methods of Using FVIII Polypeptide |
| HRP20231183T1 (hr) * | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimizirani gen faktora viii |
| EP3666283B1 (en) * | 2013-03-15 | 2022-06-08 | Bioverativ Therapeutics Inc. | Factor viii polypeptide formulations |
| US9234757B2 (en) | 2013-11-29 | 2016-01-12 | Fedex Corporate Services, Inc. | Determining node location using a variable power characteristic of a node in a wireless node network |
| US10453023B2 (en) | 2014-05-28 | 2019-10-22 | Fedex Corporate Services, Inc. | Methods and node apparatus for adaptive node communication within a wireless node network |
| US11238397B2 (en) | 2015-02-09 | 2022-02-01 | Fedex Corporate Services, Inc. | Methods, apparatus, and systems for generating a corrective pickup notification for a shipped item using a mobile master node |
| US10491479B2 (en) | 2015-07-08 | 2019-11-26 | Fedex Corporate Services, Inc. | Systems, apparatus, and methods of time gap related monitoring for an event candidate related to an ID node within a wireless node network |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| SI3411478T1 (sl) | 2016-02-01 | 2022-10-28 | Bioverativ Therapeutics Inc. | Optimirani geni dejavnika VIII |
| JP6957496B2 (ja) | 2016-03-23 | 2021-11-02 | フェデックス コーポレイト サービシズ，インコーポレイティド | 無線ノードネットワーク内のノードのブロードキャスト設定を自動調整するための無線ノードベースの方法、その方法を実行する命令を含む非一時的コンピュータ可読媒体、および無線ノードネットワークにおける自動調整ブロードキャストノード装置 |
| CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技（上海）有限公司 | 双特异性抗体及其制备方法与用途 |
| WO2018032638A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| JP7370974B2 (ja) | 2017-11-07 | 2023-10-30 | ラニ セラピューティクス， エルエルシー | 嚥下可能薬物送達デバイスを使用する腸管組織への送達のための凝固因子調製物 |
| WO2019175384A2 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
| US20210023209A1 (en) | 2018-03-16 | 2021-01-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes |
| EP3765065A2 (en) | 2018-03-16 | 2021-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes |
| US20210024631A1 (en) * | 2018-03-28 | 2021-01-28 | Orionis Biosciences, Inc. | Bi-functional proteins and construction thereof |
| JP2021523878A (ja) * | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病ａを処置する方法 |
| JP2022530615A (ja) * | 2019-05-03 | 2022-06-30 | ラニ セラピューティクス， エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の組織への送達のための凝固因子調製物 |
| JP2022537200A (ja) | 2019-06-19 | 2022-08-24 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病および低骨ミネラル密度を処置するための方法および組成物 |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| JPH0788399B2 (ja) | 1985-04-12 | 1995-09-27 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新規プロコアギュラント蛋白質 |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| ATE87663T1 (de) | 1986-01-03 | 1993-04-15 | Genetics Inst | Verfahren zur herstellung von faktor-viii:c-typ- proteinen. |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| ATE148171T1 (de) | 1989-02-21 | 1997-02-15 | Univ Washington | Modifizierte formen von fortpflanzungshormonen |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US5563045A (en) * | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| WO2001058957A2 (en) | 2000-02-11 | 2001-08-16 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
| ES2319745T3 (es) * | 2001-10-05 | 2009-05-12 | Expression Therapeutics, Llc | Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso. |
| DK1463751T3 (da) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albuminfusionsproteiner. |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PL2077121T3 (pl) | 2003-05-06 | 2011-07-29 | Syntonix Pharmaceuticals Inc | Białka chimeryczne o strukturze czynnik krzepliwości krwi VII-FC do leczenia zaburzenia hemostatycznego |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| NO20210454A1 (no) | 2004-11-12 | 2007-06-27 | Bayer Healthcare Llc | Setedirigert modifikasjon av FVIII |
| SG123635A1 (en) | 2004-12-28 | 2006-07-26 | Nanoscience Innovation Pte Ltd | Nanostructured zinc oxide and a method of producing the same |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| SI2402754T2 (sl) | 2006-03-06 | 2023-09-29 | Amunix Operating Inc. | Nestrukturirani rekombinantni polimeri in njihove uporabe |
| AU2007338298B2 (en) * | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| DE602008005596D1 (de) | 2007-06-21 | 2011-04-28 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| US8239182B2 (en) | 2007-12-04 | 2012-08-07 | Spansion Llc | Data transmission system-on-chip memory model based validation |
| MX362028B (es) | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. |
| SG181130A1 (en) | 2009-12-06 | 2012-07-30 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| EP2591099B1 (en) | 2010-07-09 | 2020-11-18 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
| US9611310B2 (en) * | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| DK3513804T3 (da) * | 2011-07-08 | 2022-06-20 | Bioverativ Therapeutics Inc | Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf |
-
2012
- 2012-07-06 DK DK18211156.7T patent/DK3513804T3/da active
- 2012-07-06 RS RS20190355A patent/RS58578B1/sr unknown
- 2012-07-06 WO PCT/US2012/045784 patent/WO2013009627A2/en active Application Filing
- 2012-07-06 ES ES12811808T patent/ES2722209T3/es active Active
- 2012-07-06 JP JP2014519074A patent/JP2014522838A/ja not_active Withdrawn
- 2012-07-06 KR KR1020147003130A patent/KR101829603B1/ko active IP Right Grant
- 2012-07-06 PT PT182111567T patent/PT3513804T/pt unknown
- 2012-07-06 SI SI201231567T patent/SI2729161T1/sl unknown
- 2012-07-06 MX MX2014000202A patent/MX350581B/es active IP Right Grant
- 2012-07-06 KR KR1020187003966A patent/KR102110736B1/ko active IP Right Grant
- 2012-07-06 TW TW109104200A patent/TWI764092B/zh active
- 2012-07-06 LT LTEP18211156.7T patent/LT3513804T/lt unknown
- 2012-07-06 AR ARP120102464A patent/AR087091A1/es not_active Application Discontinuation
- 2012-07-06 MY MYPI2014000038A patent/MY180714A/en unknown
- 2012-07-06 LT LTEP12811808.0T patent/LT2729161T/lt unknown
- 2012-07-06 CA CA2841066A patent/CA2841066C/en active Active
- 2012-07-06 EP EP22163636.8A patent/EP4169525A1/en active Pending
- 2012-07-06 ES ES18211156T patent/ES2913994T3/es active Active
- 2012-07-06 PL PL18211156T patent/PL3513804T3/pl unknown
- 2012-07-06 EA EA201490039A patent/EA029045B1/ru not_active IP Right Cessation
- 2012-07-06 US US14/131,600 patent/US10010622B2/en active Active
- 2012-07-06 CN CN201280043194.2A patent/CN103796670A/zh active Pending
- 2012-07-06 AU AU2012282875A patent/AU2012282875B2/en active Active
- 2012-07-06 BR BR112014000466A patent/BR112014000466A2/pt not_active Application Discontinuation
- 2012-07-06 HR HRP20220639TT patent/HRP20220639T1/hr unknown
- 2012-07-06 HU HUE12811808A patent/HUE043763T2/hu unknown
- 2012-07-06 PT PT12811808T patent/PT2729161T/pt unknown
- 2012-07-06 DK DK12811808.0T patent/DK2729161T3/en active
- 2012-07-06 TW TW101124461A patent/TWI626947B/zh active
- 2012-07-06 RS RS20220491A patent/RS63241B1/sr unknown
- 2012-07-06 CN CN201710301935.7A patent/CN107261122A/zh active Pending
- 2012-07-06 EP EP12811808.0A patent/EP2729161B1/en active Active
- 2012-07-06 EP EP18211156.7A patent/EP3513804B1/en active Active
- 2012-07-06 SI SI201232000T patent/SI3513804T1/sl unknown
- 2012-07-06 PL PL12811808T patent/PL2729161T3/pl unknown
- 2012-07-06 TW TW106131035A patent/TWI687226B/zh active
-
2014
- 2014-01-06 IL IL230333A patent/IL230333B/en active IP Right Grant
- 2014-01-07 CL CL2014000024A patent/CL2014000024A1/es unknown
- 2014-01-21 CO CO14011134A patent/CO6940381A2/es unknown
-
2016
- 2016-07-15 AU AU2016204986A patent/AU2016204986B2/en active Active
-
2017
- 2017-02-20 JP JP2017028814A patent/JP2017088623A/ja active Pending
-
2018
- 2018-04-27 AU AU2018202936A patent/AU2018202936B2/en active Active
- 2018-05-29 US US15/991,629 patent/US10881742B2/en active Active
- 2018-11-29 JP JP2018223631A patent/JP7273487B2/ja active Active
-
2019
- 2019-03-19 CY CY20191100325T patent/CY1122900T1/el unknown
- 2019-03-19 HR HRP20190535TT patent/HRP20190535T1/hr unknown
-
2020
- 2020-01-06 IL IL271870A patent/IL271870B/en unknown
- 2020-12-04 US US17/112,280 patent/US20210220476A1/en active Pending
-
2021
- 2021-10-18 JP JP2021170188A patent/JP2022003096A/ja not_active Withdrawn
-
2023
- 2023-07-31 JP JP2023124309A patent/JP2023134851A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220639T1 (hr) | Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe | |
| JP2013534426A5 (hr) | ||
| JP2013512678A5 (hr) | ||
| HRP20200503T1 (hr) | Fuzijski proteini | |
| JP2015532307A5 (hr) | ||
| JP5715622B2 (ja) | 血小板レベルを増大させるためのペプチド療法 | |
| JP2016516722A5 (hr) | ||
| JP2017503509A5 (hr) | ||
| ES2683844T3 (es) | Proteína de fusión que comprende una interleucina 4 e interleucina 10 | |
| JP2010518079A5 (hr) | ||
| BRPI0617823A2 (pt) | uso de sdf-1 para o tratamento e/ou prevenção de doenças neurológicas e composição farmacêutica | |
| JP6800916B2 (ja) | 第ｉｘ因子ポリペプチド製剤 | |
| JP2013518090A5 (hr) | ||
| RU2010144014A (ru) | Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств | |
| RU2017102381A (ru) | Терапевтическое применение костных морфогенетических белков | |
| JP2016506727A5 (hr) | ||
| US20070134260A1 (en) | Use of clusterin for the treatment and/or prevention of peripheral neurological diseases | |
| JP2012517425A5 (hr) | ||
| JP2020504081A5 (hr) | ||
| JP2013535965A5 (hr) | ||
| JP2010509345A5 (hr) | ||
| ES2609927T3 (es) | Composiciones y métodos para tratamientos durante periodos no agudos después de lesiones neurológicas del SNC | |
| KR20190084287A (ko) | 연골 손상 및 관절염 치료 방법 및 조성물 | |
| JP2014515595A5 (hr) | ||
| JP2017524675A5 (hr) |